RNS Number: 6642T

JPMorgan Global Emerging Mkts I.T.

01 August 2025

LONDON STOCK EXCHANGE ANNOUNCEMENT

JPMORGAN GLOBAL EMERGING MARKETS INCOME TRUST PLC

(the 'Company')

Compliance with Market Abuse Regulation

Legal Entity Identifier: 549300OPJXU72JMCYU09

Information disdosed in accordance with the Market Abuse Regulation ('MAR')

The Company announces that it is satisfied that all inside information which the Directors and the Company may have in the period leading up to the announcement of its annual financial results for the year ended 31st July 2025 has previously been, and will continue to be, notified to the London Stock Exchange via a regulatory information service. Therefore, the Company is not prohibited from dealing in its own securities.

The mandatory dosed period under MAR will commence on 23rd September 2025 and will last until the annual financial results in respect of the year ended 31st July 2025 are published, which is expected on or around 31st October 2025.

If, in the period leading up to the announcement of the annual financial results, the Company or its Directors of the Company come into the possession of any inside information, this will be notified to the London Stock Exchange without delay and before any such transactions are undertaken.

JPMorgan Funds Limited, Company Secretary 1st August 2025

For further information, please contact:

JPMorgan Funds Limited

Telephone: 0800 20 40 20 (or +44 1268 44 44 70) E-mail: jpmam.investment.trusts@jpmorgan.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.